We are a clinical-stage biotech company pioneering first-in-class treatments to revolutionize metabolic health. Our mission is to redefine the management of diabetes, obesity, and other metabolic diseases, which impact millions globally. By harnessing our groundbreaking technology, we aim to transform therapeutic options across a spectrum of metabolic disorders, through the development of small molecules with distinct and novel signaling profiles.
Our dedication to innovation, coupled with a highly skilled team, has advanced our lead asset, a treatment for type 2 diabetes, through Phase I clinical trials. Phase 2 clinical trials are expected to start in 2025. Additionally, we are advancing another promising compound, currently in preclinical stages, which has shown remarkable potential to improve body composition. This molecule will move into IND preparatory studies in 2025.
Since our inception, we have successfully raised over EUR 20 million in funding from prominent investors, including Flerie Invest, Korea Investment Partners (KIP), and a network of private investors. Our work has also been recognized by international organizations, securing over EUR 1.5 million in non-dilutive grants from Eurostars and SweLife, affirming the groundbreaking nature of our receptor signaling discoveries.
